24,885 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Acquired by Assenagon Asset Management S.A.

Share on StockTwits

Assenagon Asset Management S.A. acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the third quarter, Holdings Channel reports. The firm acquired 24,885 shares of the company’s stock, valued at approximately $2,242,000.

Other institutional investors have also recently bought and sold shares of the company. OmniStar Financial Group Inc. acquired a new stake in shares of Neurocrine Biosciences during the 3rd quarter valued at $277,000. Treasurer of the State of North Carolina boosted its stake in shares of Neurocrine Biosciences by 6.0% during the 2nd quarter. Treasurer of the State of North Carolina now owns 61,421 shares of the company’s stock valued at $5,186,000 after buying an additional 3,450 shares during the period. Colony Group LLC acquired a new stake in shares of Neurocrine Biosciences during the 2nd quarter valued at $1,427,000. International Biotechnology Trust PLC boosted its stake in shares of Neurocrine Biosciences by 51.4% during the 2nd quarter. International Biotechnology Trust PLC now owns 156,800 shares of the company’s stock valued at $13,239,000 after buying an additional 53,200 shares during the period. Finally, Perceptive Advisors LLC boosted its stake in shares of Neurocrine Biosciences by 7.1% during the 2nd quarter. Perceptive Advisors LLC now owns 4,023,862 shares of the company’s stock valued at $339,734,000 after buying an additional 265,200 shares during the period. 96.09% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on the stock. ValuEngine raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a research note on Wednesday, July 31st. CIBC assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, July 16th. They set an “outperform” rating and a $100.00 target price for the company. Oppenheimer assumed coverage on shares of Neurocrine Biosciences in a research note on Tuesday, July 16th. They set an “outperform” rating and a $100.00 target price for the company. Piper Jaffray Companies lifted their target price on shares of Neurocrine Biosciences from $103.00 to $111.00 and gave the company an “overweight” rating in a research note on Tuesday, July 30th. Finally, BidaskClub lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a research note on Friday, September 13th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus target price of $106.21.

In related news, insider Malcolm Lloyd-Smith sold 9,956 shares of Neurocrine Biosciences stock in a transaction on Monday, October 14th. The shares were sold at an average price of $90.85, for a total value of $904,502.60. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Kevin Charles Gorman sold 80,000 shares of Neurocrine Biosciences stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $95.31, for a total transaction of $7,624,800.00. Following the completion of the transaction, the chief executive officer now owns 468,508 shares in the company, valued at approximately $44,653,497.48. The disclosure for this sale can be found here. Insiders have sold a total of 179,349 shares of company stock worth $17,006,816 in the last 90 days. 4.30% of the stock is owned by insiders.

Neurocrine Biosciences stock opened at $95.78 on Friday. The company has a market capitalization of $8.87 billion, a P/E ratio of 435.36, a P/E/G ratio of 5.97 and a beta of 1.22. The firm’s fifty day simple moving average is $95.00 and its 200-day simple moving average is $88.09. The company has a current ratio of 7.44, a quick ratio of 7.32 and a debt-to-equity ratio of 0.96. Neurocrine Biosciences, Inc. has a 1-year low of $64.72 and a 1-year high of $116.48.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, July 29th. The company reported $0.37 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.13. The business had revenue of $183.58 million for the quarter, compared to the consensus estimate of $161.79 million. Neurocrine Biosciences had a net margin of 2.98% and a return on equity of 0.46%. Neurocrine Biosciences’s revenue for the quarter was up 89.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) EPS. On average, equities research analysts predict that Neurocrine Biosciences, Inc. will post 0.68 earnings per share for the current year.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company offers INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; ORILISSA, a gonadotropin-releasing hormone (GnRH) antagonist for use in women's health.

See Also: Why do companies engage in swaps?

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Mammoth Energy Services  Trading 9.6% Higher  After Insider Buying Activity
Mammoth Energy Services Trading 9.6% Higher After Insider Buying Activity
Canopy Growth  Shares Gap Down  on Analyst Downgrade
Canopy Growth Shares Gap Down on Analyst Downgrade
Short Interest in Castle Biosciences  Drops By 5.6%
Short Interest in Castle Biosciences Drops By 5.6%
Traders Purchase Large Volume of Bilibili Put Options
Traders Purchase Large Volume of Bilibili Put Options
Eidos Therapeutics  Sees Strong Trading Volume After Analyst Upgrade
Eidos Therapeutics Sees Strong Trading Volume After Analyst Upgrade
Allegiance Bancshares Inc  Short Interest Update
Allegiance Bancshares Inc Short Interest Update


© 2006-2019 Ticker Report